Why the study?
Does combined measurement of serum antibody binding to panels of antigens improve diagnostic sensitivity and specificity compared to simple quantification of IgM binding to GM1 ganglioside in patients with MMN and LMN syndromes?
Does combined measurement of serum antibody binding to panels of antigens improve diagnostic sensitivity and specificity compared to simple quantification of IgM binding to GM1 ganglioside in patients with MMN and LMN syndromes?
Combined antigen panel testing improves the diagnostic accuracy for immune-mediated motor neuropathies over single anti-GM1 antibody testing.
Answers are grounded in this paper and cite their sources.
Panel testing may aid MMN/LMN diagnosis; leaves open need for prospective validation before practice change.
There is increasing evidence that multifocal motor neuropathy (MMN) and some lower motor neuron (LMN) syndromes are immune-mediated and treatable. The frequent occurrence of high titers of anti-GM1 antibodies in these motor neuropathies raised hopes that serum testing would provide useful diagnostic information. Unfortunately, in routine practice, simple quantification of IgM binding to GM1 ganglioside has proved to be a test with poor sensitivity and specificity. We have found that much greater sensitivity and specificity for MMN and LMN syndromes can be obtained by determining serum antibody binding to panels of antigens, such as GM1, histone H3, and NP-9. These results suggest that combined measurement of serum antibody binding to GM1 and other antigens can provide tests that are useful in the diagnosis and management of motor neuropathy syndromes.
No takes yet. Share an insight, caveat, or question.
Kornberg et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: